Anebulo Pharmaceuticals, Inc.
NASDAQ:ANEB
1.5955 (USD) • At close January 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 3.549 | 5.6 | 2.962 | 2.27 | 0.15 |
| General & Administrative Expenses
| 4.755 | 6.183 | 3.87 | 1.344 | 0.14 |
| Selling & Marketing Expenses
| 0.005 | 0 | 0 | 0 | 0.023 |
| SG&A
| 4.76 | 6.183 | 3.87 | 1.344 | 0.023 |
| Other Expenses
| 0 | -0.041 | -0.002 | -0.001 | 0 |
| Operating Expenses
| 8.309 | 11.784 | 6.831 | 3.614 | 0.173 |
| Operating Income
| -8.309 | -11.784 | -6.831 | -3.614 | -0.173 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.107 | 0.051 | 0.006 | -26.639 | -0.001 |
| Income Before Tax
| -8.202 | -11.732 | -6.826 | -30.253 | -0.175 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.104 | -0.013 | 0.011 | -0.001 |
| Net Income
| -8.202 | -11.732 | -6.813 | -30.263 | -0.175 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.32 | -0.47 | -0.29 | -1.3 | -0.007 |
| EPS Diluted
| -0.32 | -0.47 | -0.29 | -1.3 | -0.007 |
| EBITDA
| -8.05 | -11.784 | 0.006 | -30.241 | -0.173 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |